Last reviewed · How we verify
High-dose experimental vaccine
At a glance
| Generic name | High-dose experimental vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Myalgia
- Injection Site Pain
- Headache
- Injection site pain
- Administration site pain
- Fatigue
- Malaise
- Administration site erythema
- Pyrexia
- Administration site swelling
- Arthralgia
- Injection site erythema
Key clinical trials
- The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (PHASE1)
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 (PHASE1)
- Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose experimental vaccine CI brief — competitive landscape report
- High-dose experimental vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI